MEDICAL INSTRUMENTS & SUPPLIES

Nov 13, 2026

ResMed's Chairman and CEO, Michael J. Farrell, recently exercised options for 4,993 common shares at $146.34 each and subsequently sold all of these shares at a weighted-average price of $235.3473. Following these transactions, Farrell holds 479,803 direct shares and 2,090 indirect shares through a family trust. Analysts currently rate ResMed (AU:RMD) with a Buy and a A$38.70 price target.

Nov 13, 2026

An investment of $100 in ResMed (NYSE: RMD) made 10 years ago would be worth $414.70 today, demonstrating the power of compounded returns. Over the past decade, ResMed has outperformed the market by 1.92% on an annualized basis, achieving an average annual return of 15.08%. The company currently holds a market capitalization of $33.60 billion.

Nov 13, 2026

GE HealthCare Technologies Inc. (GEHC) announced the formation of the MAGNUS Neuro Alliance, a research network dedicated to advancing neuroscience using its ultra-high-gradient, head-only 3.0T MR system. This alliance aims to foster collaboration among leading researchers and clinicians, exploring advanced MRI techniques and developing novel imaging biomarkers for neurological conditions. The initiative seeks to translate scientific breakthroughs into improved patient outcomes, with participating institutions including major universities and hospitals worldwide.

Nov 13, 2026

Intuitive Surgical (NASDAQ: ISRG) has significantly outperformed the market over the past two decades, achieving an average annual return of 20.31%. An initial investment of $100 in ISRG stock 20 years ago would now be worth $4,011.54. This highlights the substantial impact of compounded returns on investment growth over time.

Nov 13, 2026

This article examines why ResMed (ASX:RMD) is attracting attention, highlighting its position within the ASX 50 and ASX 200 benchmarks. It discusses the importance of operating evidence, such as customer behavior and project milestones, over short-term market sentiment. The piece also touches on potential sources of support like clinical demand and product adoption, as well as risks including regulatory requirements and cost pressures.

Nov 13, 2026

This report analyzes Repligen Corporation (NASDAQ: RGEN), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details three AI-generated trading strategies: a long position trading strategy, a breakout momentum strategy, and a tactical short risk hedging strategy, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis, showing support and resistance levels.

Nov 13, 2026

West Pharmaceutical Services (WST) stock, after a 54.7% return over the past year, appears to be overvalued by approximately 29% based on discounted cash flow (DCF) analysis. While the company's business model supports steady cash generation, the current share price of $411.30 significantly exceeds the DCF outcome, suggesting the market has already priced in much of its future potential. However, Simply Wall St's analyst consensus narrative indicates the stock could be 13% undervalued, contingent on successful execution of higher-margin opportunities.

Nov 12, 2026

Life sciences company Azenta (AZTA) saw its stock dip over 7% on Thursday, trading at $45.25, as investors booked profits. This retreat followed a significant 21% surge the previous day after the company released its quarterly report, marking its fifth gain in seven sessions.

Nov 12, 2026

Intuitive Surgical's stock has dropped 22% over the past year despite a 30% rise in systems revenue in Q3 2026, driven by strong demand for its new da Vinci 5 surgical robot. The company's future performance will depend on whether the increased adoption of newer, richer product mix can offset anticipated instrument price cuts and a slowing U.S. procedure growth. Investors should closely watch da Vinci instrument and accessory revenue per procedure, which will be affected by these factors.

Nov 12, 2026

Alcon's third-quarter sales increased by 5% to $2.7 billion, but implantables experienced a 2% decline due to heightened competition in the US premium IOL market. To counter this, Alcon is relying on its new Vivity Pro lens, launching in January, an RxSight license, and the recent Neurotech acquisition to stimulate growth and outpace the estimated 3% market expansion. The company aims to restore growth in its implantables business after losing US premium intraocular lens share.

Nov 12, 2026

This article provides a detailed analysis of Merit Medical Systems Inc. (NASDAQ: MMSI), outlining weak near and mid-term sentiment and a neutral long-term outlook. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop levels. The analysis also highlights a significant short setup with an exceptional risk-reward ratio.

Nov 12, 2026

City Therapeutics has dosed the first participant in its phase 1 trial of CITY-RBP4, an investigational RNA interference (RNAi) therapeutic for Stargardt disease type 1 (STGD1). This therapy aims to silence RBP4 expression in the liver to reduce vitamin A delivery to the eye and slow retinal damage. The milestone occurs as the FDA reviews Belite Bio’s tinlarebant, another RBP4-targeting therapy, for potential approval, highlighting a rapidly advancing pipeline for Stargardt disease.

Nov 12, 2026

Azenta, a company specializing in biological sample storage and gene synthesis services, has provided fiscal 2027 guidance expecting revenue between $648 million and $660 million, with organic growth of 3% to 5% and an adjusted EBITDA margin expansion of 200 to 250 basis points. The company also reported a 5% increase in fourth-quarter revenue to $167 million and detailed its recent investments in gene synthesis technology, anticipating these deals to contribute to future growth. Despite a GAAP loss in fiscal 2026 due to a goodwill impairment, Azenta projects improved free cash flow and continued organic growth in the upcoming quarter.

Nov 12, 2026

Alcon's stock declined after the eye-care company narrowed its annual earnings outlook and reported weaker implantable-product sales, particularly due to US competitive pressure in intraocular lenses. Despite stronger quarterly earnings and cash generation, the durability of growth is being questioned, especially as a significant tariff refund artificially boosted operating income. Analysts expressed uncertainty regarding the company's growth trajectory without this one-off benefit.

Nov 11, 2026

This article examines REA Group (ASX:REA), ResMed (ASX:RMD), and Wesfarmers (ASX:WES) as potential long-term investments, highlighting their strong market positions and growth drivers. REA Group benefits from its dominant property website, ResMed from recurring demand for sleep apnoea devices, and Wesfarmers from its diversified retail brands. However, each company faces risks such as regulation, competition, and consumer spending pressures.

Nov 11, 2026

Alcon Inc. (ALC) reported Q3 2026 net sales of $2.7 billion, a 5% increase year-over-year, driven by strong performance in Vision Care and Surgical equipment. Despite competitive pressures in the U.S. premium intraocular lens market, the company maintained its full-year guidance of approximately 6% sales growth and 12-14% core diluted EPS growth. Alcon also announced the acquisition of Neurotech Pharmaceuticals to expand its retina portfolio and discussed upcoming product launches like Vivity Pro and BRYTLY, emphasizing continued innovation and market premiumization.

Nov 11, 2026

Alcon Inc. reported Q3 2026 net sales of $2.7 billion, a 5% increase year-over-year, driven by strong performance in Vision Care and Surgical equipment. Despite competitive pressures in the U.S. premium intraocular lens market, the company narrowed its full-year 2026 guidance, expecting approximately 6% sales growth and 12-14% core diluted EPS growth. Alcon also acquired Neurotech Pharmaceuticals to expand its retina portfolio and announced FDA approval for BRYTLY, a new redness reliever eye drop.

Nov 11, 2026

Alcon's shares fell after its Q3 results revealed a decline in implantable lens sales due to US competition and operating profit boosted by a one-off $58 million tariff refund. While overall sales rose 5% to $2.72 billion, intraocular lens sales dropped, causing analysts to note that without the refund, operating profit would have missed expectations. The company narrowed its 2026 sales and core EPS guidance amidst uncertainty about its growth trajectory.

Nov 11, 2026

KORU Medical Systems reported an 11% increase in revenue, reaching $11.6 million, for the third quarter ended September 30, 2026. The growth was driven by a consistent recurring patient base and increased domestic core revenues, despite a decrease in international core revenues. The company also achieved positive net income and adjusted EBITDA, and updated its full-year 2026 guidance, raising revenue and year-end cash balance projections.

Nov 11, 2026

Angel Aligner has announced six new innovations for 2027, as detailed in a press release contributed by Business Wire. The article also lists several related news items concerning Angelalign Technology's financial results, patent disputes, and market performance in Europe and North America.

Nov 11, 2026

Alcon (NYSE: ALC) reported third-quarter adjusted earnings of 91 cents per share, surpassing estimates, but sales of $2.717 billion missed Wall Street expectations. The company's Implantables segment saw a 2% decline due to competitive launches and reimbursement challenges, while Consumables and Contact Lenses segments experienced growth. Alcon narrowed its fiscal 2026 adjusted earnings and sales guidance, with an analyst reiterating a Buy rating despite a softer market outlook.

Nov 11, 2026

Align Technology has appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors, replacing the retiring Andrea Saia. Blackford brings extensive experience in global healthcare, medical technology, and digital innovation from his roles at iRhythm Technologies, Dexcom, NuVasive Inc., and Zimmer Holdings. Align Technology credits Saia for her significant contributions to the company's growth and strategic oversight during her 13-year tenure.

Nov 11, 2026

Bionano Genomics Inc. (BNGO) reported a 12% year-over-year increase in total revenue to $8.3 million for Q3 2026, driven by record flow cell sales and strong consumables and instrument revenue growth. Despite a decline in software revenue, the company achieved improved gross margins and reduced operating expenses. BNGO reiterated its full-year 2026 revenue guidance and discussed efforts to address supply constraints and expand OGM adoption and reimbursement.

Nov 11, 2026

AtriCure board member B. Kristine Johnson sold 2,452 shares of company stock for a total of $143,392 on November 10, according to an SEC filing. This insider transaction occurred while AtriCure shares were trading up by 0.81% at $56.72. The article also provides a detailed financial overview of AtriCure, highlighting its revenue growth, gross margin, EPS, debt management, and various valuation metrics.

Nov 11, 2026

Stereotaxis reported a 20% year-over-year revenue increase to $8.9 million for Q3 2026, driven by new system installations and increased catheter sales. The company is undergoing two major transformations: shifting to easily installed systems like Genesis X and developing disposable interventional catheters for recurring revenue. Despite supply constraints for Magic catheters, Stereotaxis is pursuing alternative options and secured a convertible note financing of up to $24 million to support operations until anticipated profitability within the next year.

Nov 10, 2026

Bionano Genomics reported a third-quarter loss that missed consensus estimates, with revenue growth slowing despite record flowcell sales. While cost controls narrowed the GAAP net loss and the outlook for optical genome mapping (OGM) improved with potential new coverage, the company faces significant challenges, including thinning cash reserves and the need for substantial financing to support its ambitious 2027 growth and adjusted EBITDA neutrality targets.

Nov 10, 2026

TELA Bio reported Q3 2026 revenue of $19 million, an 8% year-over-year decrease, despite sequential growth in U.S. hernia revenue and 18% growth in European revenue. The company implemented a $17 million cost reduction plan, improved its adjusted EBITDA loss by 55% sequentially, and regained Nasdaq compliance. Strategic shifts include a focus on high-ASP procedures, strengthened clinical validation with new publications, and FDA clearance for the Liora Monofilament Scaffold, aiming for a return to double-digit growth.

Nov 10, 2026

Bionano Genomics reported strong Q3 2026 financial results, with a 12% year-over-year revenue increase to $8.3 million, driven by a record 9,870 nanochannel array flow cell sales. The company is strategically shifting towards profitable growth, focusing on clinical adoption of Optical Genome Mapping (OGM) and achieving significant advancements in OGM reimbursement and state approvals. Bionano reiterated its full-year 2026 revenue guidance of $31 million to $33 million and aims for adjusted EBITDA neutrality by the end of 2027.

Nov 10, 2026

GE HealthCare Technologies Inc. (GEHC) has enhanced its Vscan Air handheld ultrasound system with two new AI-assisted capabilities: Lung Guidance and AutoAS. These tools are designed to streamline lung ultrasound image acquisition and aid in assessing moderate-to-severe aortic stenosis at the point of care. The expansion of its cardiopulmonary AI suite aims to help clinicians make more informed decisions, especially when access to formal imaging or specialist interpretation is limited, potentially strengthening GE HealthCare's position in the point-of-care ultrasound market.

Nov 10, 2026

Harvard Bioscience, Inc. (HBIO) reported a narrower-than-expected loss for Q3 2026, with a loss per share of $0.06, beating analyst forecasts. The company's revenue of $22.2 million also surpassed consensus estimates and represented an 8.0% increase year-over-year. Despite a challenging environment, Wall Street analysts maintain a constructive view on the stock.

Nov 10, 2026

Orasure Technologies has joined the World Coalition on Sickle Cell Disease, an international public-private partnership aimed at improving care for individuals affected by sickle cell disease globally. The company will contribute its expertise in diagnostics, particularly point-of-care tests, to help strengthen the connection between diagnosis and treatment. This collaboration seeks to facilitate earlier and more accurate diagnoses, especially in regions with limited medical access, and to ensure clear pathways to appropriate care and ongoing treatment.

Nov 10, 2026

OraSure Technologies announced a delay in achieving operational cash flow break-even status until the second half of 2027, citing shifting growth opportunities. Despite this, the Bethlehem-based medtech company reported revenue growth in its third quarter 2026 financial results and is focusing on expanding its HIV and Ebola testing products globally, particularly in Africa. The company's stock was down slightly after the announcement but remains up over 43% year-to-date.

Nov 10, 2026

Intuitive Surgical Inc. (ISRG) stock dropped 2.28% on Tuesday, closing at $450.04, amidst a general market downturn with the S&P 500 and Dow Jones also falling. The company's shares are currently 25.48% below their 52-week high of $603.88, which was reached on January 7th. This underperformance occurred despite the broader market's negative trend.

Nov 10, 2026

Ballard Power Systems announced that its FCmove-SC fuel cell engine will debut in the new Solaris Urbino 12 hydrogen transit bus, based on a long-term supply agreement. This collaboration aims to advance hydrogen bus technology by offering a more compact design with improved service support to reduce lifecycle costs. The FCmove-SC delivers up to 80 kilowatts of rated power and boasts a 57% increase in volumetric power density, along with features like enhanced thermal management and simplified integration.

Nov 10, 2026

Harvard Bioscience reported 8% year-over-year revenue growth in Q3 2026, reaching $22.2 million, driven by strong sales in organoids, fluidics, and respiratory devices, with a significant 31% increase in China. The company reaffirmed its full-year revenue guidance but adjusted EBITDA guidance due to product mix and channel sales impacting margins. Project Viking, their manufacturing consolidation plan, is on track for Q1 2027 completion, expected to generate substantial cost savings.

Nov 10, 2026

Van Berkom & Associates Inc. reduced its stake in Stevanato Group S.p.A. by 3.7% in the third quarter, selling 110,897 shares but still retaining over 2.8 million shares valued at about $60 million. The company reported quarterly EPS of €0.16, missing analyst expectations, while insider Mauro Stocchi also sold 13,649 shares, decreasing his direct holdings by 3.3%. Despite mixed analyst views, Stevanato Group maintains a "Moderate Buy" consensus rating on MarketBeat.

Nov 10, 2026

Intuitive Surgical (ISRG) stock has shown higher volatility and lower returns compared to the S&P 500 over the past five years, offering less compensation for its price swings. The company is facing business changes, including expected price cuts in da Vinci instrument revenue and a pending $450 million litigation settlement. Investors should monitor U.S. da Vinci procedure growth, which has been slower than international growth, as the company prepares to report again in January 2027.

Nov 10, 2026

This Zacks Analyst Blog highlights five key stocks: ASML Holding N.V., Alibaba Group Holding Ltd., Intuitive Surgical, Inc., Paul Mueller Co., and Presurance Holdings, Inc. The blog provides brief research reports on each company, detailing their recent performance, market factors, and analyst perspectives on their strengths and challenges. These reports aim to offer investors insights into the potential of these stocks.

Nov 10, 2026

CoreCivic's Executive Vice President and Chief Development Officer, Anthony L. Grande, sold 25,000 shares of company common stock on November 10, 2026, at a weighted average price of $31.49 per share. This transaction, detailed in a Form 4 filing, leaves Grande with 119,782 directly held shares. The individual sale prices for the shares ranged from $31.26 to $31.61.

Nov 10, 2026

GLP-1 drugs like Ozempic and Zepbound are significantly impacting various industries, creating winners such as drugmakers (Eli Lilly, Novo Nordisk) and contract manufacturers, while posing challenges for others. Commercial weight-loss programs like WW International have faced bankruptcy, and packaged food, alcohol, and restaurant sectors are anticipating reduced sales due to decreased appetite among users. The drugs also offer a non-surgical alternative to bariatric surgery and could affect CPAP machine makers, while employers and insurers grapple with the rising costs of coverage.

Nov 9, 2026

Repay Holdings Corporation reported a 97% year-over-year increase in third-quarter revenue to $153.4 million, driven by political media contributions and strong Business Payments growth. The integration of Kubra is progressing, exceeding synergy targets, and the company is leveraging AI for operational efficiencies and product enhancements. Despite underperformance in Consumer Payments, management is implementing changes for future growth and reiterated full-year 2026 revenue guidance of $490 million to $500 million and adjusted EBITDA of $168.5 million to $176 million.

Nov 9, 2026

Innovative Eyewear (LUCY) reported a significant surge in wholesale revenue, up 765% in Q3 2026, leading to total revenue for the first nine months of 2026 surpassing its full-year 2025 revenue. This growth is attributed to new distribution channels, including big-box retail in the U.S., optical clinics in Canada, and a distributor in Australia and New Zealand. Lucyd's camera-free, audio-first smart glasses, which are ANSI-certified and AI-agnostic, are targeting a niche in the rapidly expanding smart glasses market.

Nov 9, 2026

OraSure Technologies reported a 14% year-over-year revenue increase to $30.9 million in Q3 2026, driven by growth in diagnostic products and strategic initiatives like local manufacturing in Africa for HIV and Ebola diagnostics. The company secured FDA Emergency Use Authorization for its OraQuick Ebola 2.0 Rapid Antigen Test and anticipates full-year 2026 revenue growth of 3.8% to 5.6%, expecting accelerated growth in 2027 while aiming for cash flow from operations break-even in the second half of 2027.

Nov 9, 2026

The Bancorp Inc. reported a significant increase in third-quarter earnings per share, projecting further gains through 2028 driven by expanding fintech lending and payment activities. The company's strategy includes major fintech initiatives, operational improvements through restructuring and AI, and continued share repurchases, offsetting declining interest margins. Fintech loans and fees are growing rapidly, while the company maintains strong capital ratios despite shifts in its balance sheet composition.

Nov 9, 2026

Shares of Baxter International Inc. (BAX) rose 2.40% to $26.41, outperforming competitors and the broader market on a strong trading day. This marks the second consecutive day of gains for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw significant increases.

Nov 9, 2026

Nephros Inc. reported an 18% year-over-year revenue increase to $5.6 million in Q3 2026, with year-to-date revenue up 20% to $16.9 million and net income at $500,000. The company achieved a record 1,766 active customer sites and remains debt-free with $4.5 million in cash. Despite strong growth, gross margins declined due to higher costs and a shift towards lower-margin service revenue, while operating expenses rose due to increased headcount and professional fees.

Nov 9, 2026

Truist Financial has increased its price target for Teleflex (NYSE:TFX) to $167.00 from $142.00, maintaining a "hold" rating, which suggests an 11.04% upside. This decision aligns with a generally positive analyst sentiment, as Teleflex holds a "Moderate Buy" consensus rating and an average price target of $163.30. The medical technology company recently reported strong quarterly earnings of $2.63 per share, significantly surpassing estimates of $1.90, with revenue also slightly exceeding expectations.

Nov 9, 2026

Bio-Techne Corporation (TECH) reported strong first-quarter fiscal 2027 results, surpassing Zacks Consensus Estimates for both adjusted earnings per share and net sales. The company also announced that its shareholders have approved the merger agreement with Merck KGaA, an important step towards the completion of the $11.3 billion acquisition expected by late 2026 or early 2027. This merger aims to strengthen their global presence and service capabilities across the life sciences value chain.

Nov 9, 2026

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $105.60 against its opening share price of $80.89. The company's third-quarter revenue increased by 11.3% year-over-year to $67.97 million, slightly exceeding estimates, but its EPS of $0.65 missed the consensus and was down from the previous year. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, translating to an annual dividend of $1.00 and a 1.2% yield.